Preferential generation of IgG-producing human hybridomas against human tumor cells.
By pre-stimulating the lymphocytes of cancer patients with BCGF plus anti-mu chain specific antibody, we have generated human X human hybridomas. The resulting hybridomas preferentially produced IgG class antibody compared with those obtained from non-stimulated lymphocytes. With non-stimulated lymph-node lymphocytes, from stomach cancer patients we selected a hybrid (TOS/H8) producing IgM with broad reactivity against human tumor cells. In contrast, with pre-stimulated lymph-node lymphocytes from hepatoma patients we selected a hybrid (TOH/D5) producing IgG having a specific reactivity with HuTu80 (duodenum carcinoma).
Hagiwara
H
H
Hagiwara Institute of Health, Hyogo, Japan.
Nagao
J
J
D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000096:biosynthesis* / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002459:Cell Fusion; D006801:Humans; D006825:Hybridomas / Q000276:immunology*; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007148:Immunoglobulin mu-Chains / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000276:immunology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008934:Mitogens / Q000494:pharmacology; D009369:Neoplasms / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000954:Antigens, Surface; D007074:Immunoglobulin G; D007148:Immunoglobulin mu-Chains; D008934:Mitogens; D015847:Interleukin-4